| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (NCT05288166) | Eli Lilly and Company | 2022-04-14 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873) | Blueprint Medicines Corporation | 2022-03-04 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery (NCT04962958) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-12-27 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma (NCT04572451) | Yana Najjar | 2021-11-29 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma (NCT05030077) | Tianjin Medical University Second Hospital | 2021-10-01 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer (NCT04807166) | Wenjun Cheng | 2021-08-24 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (NCT04922047) | RenJi Hospital | 2021-06-01 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (NCT04556071) | Xiaoxiang Chen | 2020-11-06 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (NCT04566952) | Xiaoxiang Chen | 2020-10-28 |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC (NCT04518852) | Sichuan Cancer Hospital and Research Institute | 2020-09-14 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084) | Celularity Incorporated | 2020-05-12 |
| Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) (NCT03711110) | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | 2019-08-02 |
| Anlotinib in Metastatic HER2 Negative Breast Cancer (NCT04002284) | Peng Yuan | 2018-07-12 |
| Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA (NCT05814224) | Centro di Riferimento Oncologico - Aviano | 2018-05-22 |
| Avelumab in Refractory Testicular Germ Cell Cancer. (NCT03403777) | National Cancer Institute, Slovakia | 2017-11-15 |
| Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study (NCT03284255) | Shanghai Bio-heart Biological Technology Co., Ltd. | 2017-09-11 |
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. (NCT03606369) | Instituto Nacional de Cancerologia de Mexico | 2015-11-05 |
| Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting? (NCT02468245) | Bassett Healthcare | 2015-01-01 |
| Tablet-based Patient Reported Outcome (NCT01991691) | University Hospital, Bonn | 2013-09-01 |
| Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography (NCT00541801) | Luzerner Kantonsspital | 2007-03-01 |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy (NCT01316458) | Novartis Pharmaceuticals | 2003-06-01 |
| Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients (NCT01169792) | Yonsei University | |